HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 172 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 0.12 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $120,836,723 | -4.1% | 3,163,265 | -9.5% | 0.01% | -7.1% |
Q2 2023 | $126,068,077 | -6.3% | 3,495,095 | -0.8% | 0.01% | -12.5% |
Q1 2023 | $134,535,323 | +73152.4% | 3,522,776 | +9.1% | 0.02% | -33.3% |
Q4 2022 | $183,660 | -99.9% | 3,227,777 | -17.9% | 0.02% | +9.1% |
Q3 2022 | $155,511,000 | -13.6% | 3,933,026 | -3.8% | 0.02% | -12.0% |
Q2 2022 | $179,900,000 | -10.5% | 4,088,642 | -18.9% | 0.02% | +4.2% |
Q1 2022 | $200,986,000 | -2.5% | 5,039,771 | -1.7% | 0.02% | 0.0% |
Q4 2021 | $206,129,000 | -3.7% | 5,126,301 | -2.6% | 0.02% | -7.7% |
Q3 2021 | $214,158,000 | -10.3% | 5,264,439 | +0.2% | 0.03% | -7.1% |
Q2 2021 | $238,640,000 | +11.8% | 5,255,208 | +2.7% | 0.03% | 0.0% |
Q1 2021 | $213,415,000 | -4.0% | 5,119,082 | -1.6% | 0.03% | -15.2% |
Q4 2020 | $222,202,000 | +68.6% | 5,202,572 | +4.7% | 0.03% | +50.0% |
Q3 2020 | $131,760,000 | -1.0% | 4,970,189 | +0.1% | 0.02% | -15.4% |
Q2 2020 | $133,088,000 | +52.0% | 4,964,144 | +2.0% | 0.03% | +23.8% |
Q1 2020 | $87,573,000 | +7.3% | 4,867,887 | +5.7% | 0.02% | +40.0% |
Q4 2019 | $81,627,000 | +4.7% | 4,603,933 | -8.4% | 0.02% | -6.2% |
Q3 2019 | $77,933,000 | -4.1% | 5,024,697 | +4.2% | 0.02% | 0.0% |
Q2 2019 | $81,269,000 | +15.0% | 4,823,062 | +9.9% | 0.02% | +14.3% |
Q1 2019 | $70,668,000 | +16.6% | 4,389,285 | +6.0% | 0.01% | 0.0% |
Q4 2018 | $60,591,000 | -7.4% | 4,141,515 | +15.0% | 0.01% | +7.7% |
Q3 2018 | $65,441,000 | +21.2% | 3,601,604 | +12.5% | 0.01% | +18.2% |
Q2 2018 | $54,011,000 | -11.8% | 3,201,596 | +2.4% | 0.01% | -15.4% |
Q1 2018 | $61,221,000 | -4.7% | 3,125,123 | -1.4% | 0.01% | -7.1% |
Q4 2017 | $64,229,000 | +28.7% | 3,170,207 | +10.5% | 0.01% | +27.3% |
Q3 2017 | $49,915,000 | +45.4% | 2,868,670 | +7.2% | 0.01% | +37.5% |
Q2 2017 | $34,322,000 | -9.2% | 2,677,194 | -8.2% | 0.01% | -11.1% |
Q1 2017 | $37,784,000 | +39.2% | 2,915,415 | +6.1% | 0.01% | +28.6% |
Q4 2016 | $27,142,000 | -24.6% | 2,747,066 | -7.8% | 0.01% | -22.2% |
Q3 2016 | $36,006,000 | +35.4% | 2,980,634 | -3.3% | 0.01% | +28.6% |
Q2 2016 | $26,600,000 | -9.4% | 3,082,218 | -0.6% | 0.01% | -12.5% |
Q1 2016 | $29,353,000 | -10.3% | 3,099,576 | +64.1% | 0.01% | 0.0% |
Q4 2015 | $32,729,000 | +20.8% | 1,888,493 | -6.4% | 0.01% | +14.3% |
Q3 2015 | $27,088,000 | -27.3% | 2,016,926 | +22.3% | 0.01% | -22.2% |
Q2 2015 | $37,251,000 | +56.0% | 1,649,750 | -1.3% | 0.01% | +80.0% |
Q1 2015 | $23,874,000 | +37.8% | 1,671,867 | -6.9% | 0.01% | +25.0% |
Q4 2014 | $17,329,000 | -0.7% | 1,795,732 | -6.4% | 0.00% | 0.0% |
Q3 2014 | $17,452,000 | -9.0% | 1,917,792 | -1.2% | 0.00% | -20.0% |
Q2 2014 | $19,181,000 | -9.3% | 1,941,445 | +16.7% | 0.01% | -16.7% |
Q1 2014 | $21,143,000 | -32.3% | 1,664,033 | -20.1% | 0.01% | -33.3% |
Q4 2013 | $31,218,000 | +35.2% | 2,082,591 | -0.4% | 0.01% | +28.6% |
Q3 2013 | $23,088,000 | +30.6% | 2,091,463 | -6.0% | 0.01% | +16.7% |
Q2 2013 | $17,684,000 | – | 2,224,311 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |